louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02034305: Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy
Official title: Pilot Study of Cough Peak Flow And Airway Clearance in Pediatric Patients With Neuromuscular Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Duchenne Muscular Dystrophy
Keywords: Airway Clearance
Duchenne Muscular Dystrophy
Peak Cough Flow
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: Respirtech, Inc.
First posted: 2014-01-13
Enrollment: 7
Sex: MALE
Minimum age (years): 6
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Boys 6-21 years of age with Duchenne Muscular Dystrophy

Brief summary: This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP ,SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.


Eligibility criteria: Inclusion Criteria:

* Age 6-21; able to cooperate with study procedures
* Duchenne Muscular Dystrophy OR Becker Muscular Dystrophy

Exclusion Criteria:

* Need for mechanical ventilation during the day
* Recent (within 2 weeks) lower respiratory tract infection

Primary outcomes:
measure: Spontaneous cough clearance
timeFrame: Assessed at multiple time points over 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Children's Hospital of Pittsburgh
state: Pennsylvania
Study officials:
References:
citation: Weiner DJ, Abdel-Hamid H, Corcoran TE. Pilot study of nuclear scintigraphy to assess cough clearance in DMD. Pediatr Pulmonol. 2022 Jul;57(7):1776-1778. doi: 10.1002/ppul.25894. Epub 2022 May 5. No abstract available.
Clinical trial NCT00332605: N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
Official title: A Double-Blind Study of N-Acetyl Cysteine Plus Naltrexone in the Treatment of Methamphetamine Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Methamphetamine Dependence
Keywords: Methamphetamine Dependence
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2006-06-01
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in combination with naltrexone in methamphetamine dependence.

Detailed description: Forty subjects with DSM-IV methamphetamine dependence will receive 8 weeks of double-blind combination medication (NAC plus naltrexone) or placebo. The hypothesis to be tested is that NAC plus naltrexone will be effective and well tolerated in patients with methamphetamine dependence compared to placebo. The proposed study will provide needed data on the treatment of a public health crisis that currently lacks a clearly effective treatment.

Eligibility criteria: Inclusion Criteria:

1. men and women age 18-65
2. current DSM-IV methamphetamine dependence.

Exclusion Criteria:

1. unstable medical illness
2. history of seizures
3. myocardial infarction within 6 months
4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential
5. any thoughts of suicide
6. lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder
7. previous treatment with N-Acetyl Cysteine or naltrexone
8. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
9. abnormal liver function tests at screening
10. diagnosis of asthma
11. current use of opiates.

Primary outcomes:
measure: Penn Craving Scale
timeFrame: beginning and at each visit until the end of their participation in the study
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Jon E Grant, MD, JD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02026505: Evaluation of Cardiotoxic Effects of Bortezomib
Official title: Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Myeloma
Heart Failure, Systolic
Cardiotoxins
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: Millennium: The Takeda Oncology Company
First posted: 2014-01-03
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients (\>18 years and \<70 years) with multiple myeloma

Brief summary: The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart.

In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here.

The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.


Eligibility criteria: Inclusion Criteria:

* diagnosis of multiple myeloma
* have a treatment plan involving greater than 4 cycles of bortezomib-based chemotherapy

Exclusion Criteria:

* pre-existing history of left ventricular systolic dysfunction
* congestive heart failure
* coronary artery disease
* significant valvular heart disease
* cardiac arrhythmias
* estimated glomerular filtration rate \<30 mL/min/1.73m2

Primary outcomes:
measure: Global longitudinal strain by echocardiography
timeFrame: 6 months
Secondary outcomes:
measure: Amount of late gadolinium enhancement by cardiac MRI
timeFrame: 6 months
measure: High-sensitivity troponin T
timeFrame: 6 months
measure: C-reactive protein
timeFrame: 6 months
measure: Serum NT-proBNP
timeFrame: 6 months
measure: Carboxyl-terminal telopeptide of collagen type I
timeFrame: 6 months
measure: Amino-terminal peptide of procollagen type III
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06135805: Impact of Fluocinonide 0,05% in Oral Lichen Planus
Official title: Impact of the Efficacy of Fluocinonide 0.05% Oral Gel in the Treatment of Oral Lichen Planus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Lichen Planus
Lead sponsor: University of Catania
Sponsor class: OTHER
First posted: 2023-11-18
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Fluocinonide 0,05% and determinate the statistical significance of the outcome variables. Oral cavity lichen is a chronic inflammatory condition affecting the mucosa of the oral cavity , which significantly reduces the quality of life of affected individuals.

Detailed description: A double-blind placebo-controlled study was conducted to evaluate the clinical efficacy of Fluocinonide 0.05% oral gel and determine the statistical significance of outcome variables.

20 patients with Oral Lichen Planus were divided by a randomization system, into two groups: case group treated with Fluocinonide 0.05% oral gel and applied to oral lesions 2 times a day for 1 month and a placebo group as a control group; with 2 months of follow-up.

Eligibility criteria: Inclusion Criteria:

* Clinical and histologic diagnosis of Lichen Planus Orale;
* Presence of symptoms related to Lichen Planus Orale;
* Clinical follow-up period of at least 12 weeks;
* Acceptance of informed consent

Exclusion Criteria:

* State of pregnancy or lactation; h
* Histologic signs of dysplasia;
* Medications that induce a lichenoid response (ACE inhibitors, β-blockers, etc.);
* Presence of amalgam fillings in the vicinity of lesions;
* Treatment of oral lichen in the previous 6 months from the start of the program;
* Presence of extraoral lesions (genital, skin, etc.);
* Diabetes being treated with oral hypoglycemic drugs;
* History of previous immunodeficiency;
* HIV seropositivity;
* Previous allogeneic bone marrow transplantation;
* Diagnosis of LES or other autoimmune disease

Primary outcomes:
measure: Assessment of sings
timeFrame: 3 months
Secondary outcomes:
measure: Assessment of symptoms
timeFrame: 3 months
Other outcomes:
Locations:
city: Catania
country: Italy
facility: AOU Policlinico G. Rodolico
Study officials:
affiliation: University of Catania
name: Gaetano Isola
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06086405: ECMO Braile Biomédica® in COVID-19 Patients
Official title: ECMO Braile Biomédica® in COVID-19 Patients Post-market Clinical Trial to Verify the Performance of the ECMO System
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: COVID-19
Keywords: ECMO
COVID-19
Membrane Oxygenator
Lead sponsor: Braile Biomedica Ind. Com. e Repr. Ltda.
Sponsor class: INDUSTRY
First posted: 2023-10-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients ≥ 18 years old, with a previous diagnosis of COVID-19, who were placed on ECMO using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator

Brief summary: Retrospective data collection to evaluate the gas transfer capacity of the Braile Biomédica® OxyPrime® ECMO BRCoating® Membrane Oxygenator in COVID-19 patients during the pandemic.

Detailed description: Multicenter, retrospective, non-comparative, non-randomized study to assess the clinical performance of the OxyPrime® ECMO BRCoating® Membrane Oxygenator in adult patients with COVID-19

Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 years old, with a previous diagnosis of COVID-19, who were placed on ECMO using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator, from March 2020 to July 2022, following the Instructions for Use (IFU) of the products.

Exclusion Criteria:

* Patients without a diagnosis of COVID-19

Primary outcomes:
measure: The effectiveness of the oxygenator in ensuring adequate gas exchange
timeFrame: during the first week of use
measure: The effectiveness of the set in ensuring adequate flow to the patient
timeFrame: during the use of extracorporeal membrane oxygenation
Secondary outcomes:
measure: Rate free of membrane dysfunction
timeFrame: during the use of extracorporeal membrane oxygenation
measure: Need for oxygenator due to dysfunction
timeFrame: during the use of extracorporeal membrane oxygenation
measure: Decannulation rate
timeFrame: during the use of extracorporeal membrane oxygenation
measure: Mortality rate during ECMO use
timeFrame: during the use of extracorporeal membrane oxygenation
measure: Duration of ECMO system usage
timeFrame: during the use of extracorporeal membrane oxygenation
measure: Adverse events during extracorporeal membrane oxygenation use
timeFrame: during the use of extracorporeal membrane oxygenation
Other outcomes:
Locations:
city: Lago Sul
country: Brazil
facility: Hospital Brasília
state: Brasília - DF
Study officials:
affiliation: Hospital Brasília
name: Vitor S Barzila
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01947205: Pain and Suction Curettage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Curettage
Analgesia
Paracervical Block
Paracetamol
Keywords: Curettage
analgesia
paracervical block
paracetamol
lidocaine
Dexketoprofen trometamol
Lead sponsor: Kayseri Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2013-09-20
Enrollment: 111
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Aim of the study was to investigate the analgesic efficacy of preoperative oral dexketoprofen trometamol, intravenous paracetamol, lidocaine spray and paracervical block with ultracaine on curettage procedure.


Eligibility criteria: Inclusion Criteria:

* pregnant participants between 35-48 days of gestation (5 to 7 weeks of gestation) pregnant participants with a single viable intrauterine pregnancy requesting termination of pregnancy.

Exclusion Criteria:

incomplete abortions, diabetes mellitus, tendency to bleed such as thrombocytopenia, factor deficiency and functional disorders of platelets... etc, pelvic infection, known cervical stenosis, significantly impaired respiratory or cardiac conduction functions, active liver disease, renal disease, previous adverse reaction to any of the drugs used in the study, and patients who are unable to understand how to score a 10-cm visual analog scale (VAS) pain score. Moreover, patients who described chronic pelvic pain prior to the study or patients who rated their pain level on a continuous 100-mm VAS different from 0 (no pain) just before the study were not included into study.

Primary outcomes:
measure: pain reduction
timeFrame: nine months
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Kayseri Education and Research Hospital of Medicine
Study officials:
affiliation: Kayseri Education and Research Hospital
name: Gökhan Açmaz, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Acmaz G, Aksoy H, Ozoglu N, Aksoy U, Albayrak E. Effect of paracetamol, dexketoprofen trometamol, lidocaine spray, and paracervical block application for pain relief during suction termination of first-trimester pregnancy. Biomed Res Int. 2013;2013:869275. doi: 10.1155/2013/869275. Epub 2013 Dec 24.
Clinical trial NCT05380505: Influence of Social Media Ads on Food Choice
Official title: Examining Influence of Social Media Ads on Black and White Adolescents' Food Choices
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Choices
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
First posted: 2022-05-19
Enrollment: 1252
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: The intervention is exposure to Facebook food ads that are either race congruent or race incongruent, and that have varying numbers of likes.
Primary purpose: PREVENTION

Brief summary: This is a randomized trial to examine the influence of race-congruent food marketing on social media among Black and White adolescents.

Detailed description: This randomized trial evaluates the extent to which exposure to racially congruent vs. incongruent Facebook food ads causes Black vs. White adolescents to purchase more calories for a snack

Eligibility criteria: Inclusion Criteria:

* adolescent (13-17 years of age)
* who identifies as only non-Latino White or only Black/African American
* who logs into Facebook once daily
* who can read and speak English

Exclusion Criteria:

* participants who do not meet all criteria described above.

Primary outcomes:
measure: Number of Calories Purchased
timeFrame: 15 minutes
Secondary outcomes:
measure: Attitude Toward Ad
timeFrame: 15 minutes
measure: Time Spent Viewing Ad
timeFrame: 15 minutes
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Marie Bragg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06064305: Transcriptional and Proteomic Analysis of Acute Kidney Injury
Official title: Transcriptional and Proteomic Analysis of Acute Kidney Injury
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute Kidney Injury
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
First posted: 2023-10-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 150
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: AKI patients, nephrectomy patients

Brief summary: Acute kidney injury is associated with worsened outcome for critically ill patients. Sepsis-associated and non-septic cardiothoracic surgery associated AKI have been reported, nonetheless, precise pathomechanistic differences as well as detectability of transcriptional and proteomic changes in correlation with imaging and plasma markers are unclear.

Detailed description: Acute kidney injury is a common and detrimental finding in critically ill/sepsis patients as well as non-septic patients post cardiothoracic surgery. In many cases renal replacement therapy is required and an acute kidney injury is linked to increased morbidity and mortality in intensive care patients. Using routinely obtained clinical samples as well as imaging data, this observational trial investigates the transcriptomic and proteomic determinants detectable in septic and non-septic AKI patient subsets and their correlation with outcome and AKI diagnostic parameters.

Eligibility criteria: * Inclusion criteria:

  * study consent;
  * KDIGO\>=2;
  * vasoplegia and/or sepsis or elective nephrectomy.
* Exclusion criteria:

  * Age\<18 years;
  * pregnancy/nursing;
  * preexisting CKD with eGFR\<60m/min;
  * dialysis; former ogran transplantation;
  * HIV; hematologic malignancies;
  * immunsuppression;
  * 4h post biopsy non-pausable effective anticoagulation;
  * pre-existing coagulopathy

Primary outcomes:
measure: Correlation of transcriptional and proteomic gene regulation in tissue with clinical molecular Imaging and AKI biomarkers.
timeFrame: Through study completion, an average of 1 year.
Secondary outcomes:
measure: Further organ failure based on systemic assessment
timeFrame: Through study completion, an average of 1 year.
measure: RRT incidence
timeFrame: 28 days
measure: ICU length of stay
timeFrame: Through study completion, an average of 1 year.
measure: Hospital length of stay
timeFrame: Through study completion, an average of 1 year.
measure: Mortality
timeFrame: 28 day
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital Muenster
name: Alexander Zarbock, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00666705: A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
Official title: An Open Label Phase 4 Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Keywords: maraviroc
raltegravir
drug interaction study
healthy volunteers
Lead sponsor: ViiV Healthcare
Sponsor class: INDUSTRY
Collaborators: name: Pfizer
First posted: 2008-04-25
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.

Detailed description: Drug interaction study

Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between 18 and 55 years of age.

Exclusion Criteria:

* Evidence or history of clinically significant disease or clinical findings at screening

Primary outcomes:
measure: Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ)
timeFrame: Days 11 and 14
measure: Maraviroc Pharmacokinetic (PK) Parameter: Maximum Concentration (Cmax)
timeFrame: Days 11 and 14
measure: Raltegravir Pharmacokinetics (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ)
timeFrame: Days 3 and 14
measure: Raltegravir Pharmacokinetics (PK) Parameter: Maximum Concentration (Cmax)
timeFrame: Days 3 and 14
Secondary outcomes:
Other outcomes:
measure: Maraviroc Pharmacokinetic (PK) Parameter: 12-Hour Trough Concentration (C12)
timeFrame: Days 11 and 14
measure: Raltegravir Pharmacokinetics (PK) Parameter: 12-Hour Trough Concentration (C12)
timeFrame: Days 3 and 14
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02598505: Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
Official title: Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Heart Failure
Lead sponsor: Centro Cardiologico Monzino
Sponsor class: OTHER
Collaborators: name: Novartis
First posted: 2015-11-06
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purposes of this study are:

1. To confirm safety of Indacaterol in stable Heart Failure.
2. To determine whether beta 2 alveolar receptor stimulation by Indacaterol is able to ameliorate lung diffusion in heart Failure patients treated with beta blockers.
3. To compare the effects of Indacaterol in patients treated with a non-selective beta blocker (Carvedilol) and a beta 1-selective beta blocker (Bisoprolol).


Eligibility criteria: Inclusion Criteria:

* Male and female adults aged ≥ 18 years who have signed an Informed Consent Form.
* Patients with light chronic obstructive pulmonary disease never treated with bronchodilator drugs
* Co-operative patients
* Patients with a clinical diagnosis of chronic heart failure (HF)
* chronic myeloproliferative disorder with ejection fraction \< 40% with B Blockers therapy since at least 2 months. Optimized and individually tailored drug treatment including B blocker (Carvedilol or bisoprolol)
* Capability of performing Cardiopulmonary Exercise Test and lung diffusion test

Exclusion Criteria:

History or clinical documentation of:

* pulmonary embolism
* primary valvular heart disease
* pericardial disease
* severe obstructive lung disease
* significant peripheral vascular disease
* exercise-induced angina, st changes, or severe arrhythmias.
* Patients with diabetes Type I or uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or HbA1c \> 8.0 % of total hemoglobin measured.
* Use of bronchodilators.
* Patients with a history (or family history) of long QT syndrome or whose corrected QT interval interval (Fridericia) measured at Visit 2 is prolonged: \>450 ms (males) or \>470 ms (females) as assessed by the central electrocardiogram (ECG) interpretation.

Primary outcomes:
measure: measurement of change in lung diffusion of carbon monoxide (CO).
timeFrame: day 0, 60, 74, 134
measure: measurement of change in membrane diffusion (Dm)
timeFrame: day 0, 60, 74, 134
measure: measurement of change in capillary volume (Vc)
timeFrame: day 0, 60, 74, 134
measure: measurement of change in lung diffusion of NO (Nitric Oxide)
timeFrame: day 0, 60, 74, 134
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Centro Cardiologico Monzino
state: MI
Study officials:
affiliation: Centro Cardiologico Monzino
name: Piergiuseppe Agostoni, MD
role: PRINCIPAL_INVESTIGATOR
References: